1. Home
  2. QURE

as 06-30-2025 12:33pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Founded: 1998 Country:
Netherlands
Netherlands
Employees: N/A City: AMSTERDAM
Market Cap: 725.4M IPO Year: 2007
Target Price: $37.20 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.37 EPS Growth: N/A
52 Week Low/High: $3.73 - $19.18 Next Earning Date: 07-31-2025
Revenue: $20,201,000 Revenue Growth: 6.30%
Revenue Growth (this year): -21.83% Revenue Growth (next year): 278.91%

QURE Daily Stock ML Predictions

Stock Insider Trading Activity of uniQure N.V. (QURE)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
POST LEONARD E QURE Director Jun 20 '25 Sell $14.45 2,112 $30,518.40 29,937
Kaye Jack QURE Director Jun 20 '25 Sell $14.45 2,112 $30,518.40 20,439
Meek David D. QURE Director Jun 20 '25 Sell $14.45 2,112 $30,518.40 34,190
Gut Robert QURE Director Jun 20 '25 Sell $14.45 3,336 $48,205.20 56,879
Springhorn Jeremy P. QURE Director Jun 20 '25 Sell $14.45 2,112 $30,518.40 37,694
Balachandran Madhavan QURE Director Jun 20 '25 Sell $14.45 2,112 $30,518.40 37,697
Potts Jeannette QURE Chief Legal Officer Jun 16 '25 Sell $15.14 4,670 $70,703.80 115,073

Share on Social Networks: